{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:34Z","timestamp":1787009614036,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of tofacitinib in treatment-refractory inflammatory myositis in a real-world clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with refractory inflammatory myositis treated with tofacitinib from a single urban centre in Vancouver, British Columbia, Canada, were included from June 2016 to December 2022. The medical records of these patients were retrospectively reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 41 patients were included, 23 with classic DM, 12 with amyopathic DM (ADM) and six with PM phenotype. The patients failed an average of four to five non-steroidal immunosuppressants before initiation of tofacitinib. In the classic DM and ADM group, tofacitinib offered clinically and statistically significant cutaneous improvement. In all myositis patients including the PM phenotype, no meaningful muscle strength response to tofacitinib was observed. 53.7% of the patients discontinued tofacitinib due to lack of benefit or death. Of the 19 patients who remained on tofacitinib at the conclusion of this study, tofacitinib demonstrated clinically and statistically significant improvement in cutaneous disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tofacitinib appears to be highly effective in targeting cutaneous manifestations in classic DM and ADM; however, minimal benefit in muscle strength in the DM or PM phenotype were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead404","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T10:53:18Z","timestamp":1692183198000},"page":"1432-1436","source":"Crossref","is-referenced-by-count":17,"title":["Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-9292","authenticated-orcid":false,"given":"Madelaine","family":"Beckett","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of British Columbia , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Bonnardeaux","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Department of Internal Medicine, University of Montreal , Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3035-0522","authenticated-orcid":false,"given":"Jan","family":"Dutz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Dermatology, University of British Columbia , Vancouver, BC, Canada"},{"name":"Arthritis Research Canada , Vancouver, BC, Canada"},{"name":"Division of Rheumatology, Vancouver General Hospital , Vancouver, BC, Canada"},{"name":"BC Children's Hospital Research Center , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-3744","authenticated-orcid":false,"given":"Kamran","family":"Shojania","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of British Columbia , Vancouver, BC, Canada"},{"name":"Arthritis Research Canada , Vancouver, BC, Canada"},{"name":"Division of Rheumatology, Vancouver General Hospital , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-3209","authenticated-orcid":false,"given":"Fergus","family":"To","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of British Columbia , Vancouver, BC, Canada"},{"name":"Division of Rheumatology, Vancouver General Hospital , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Obrzut","sequence":"additional","affiliation":[{"name":"Arthritis Research Canada , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-663X","authenticated-orcid":false,"given":"J","family":"Avi\u00f1a-Zubieta","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of British Columbia , Vancouver, BC, Canada"},{"name":"Arthritis Research Canada , Vancouver, BC, Canada"},{"name":"Division of Rheumatology, Vancouver General Hospital , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-6959","authenticated-orcid":false,"given":"Kun","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of British Columbia , Vancouver, BC, Canada"},{"name":"Division of Rheumatology, Vancouver General Hospital , Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"2024050221001165500_kead404-B1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024050221001165500_kead404-B2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024050221001165500_kead404-B3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024050221001165500_kead404-B4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024050221001165500_kead404-B5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2024050221001165500_kead404-B6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.41944","article-title":"Long-term extension study of tofacitinib in refractory dermatomyositis","volume":"74","author":"Paik","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024050221001165500_kead404-B7","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1093\/rheumatology\/keab421","article-title":"Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series","volume":"60","author":"Shneyderman","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024050221001165500_kead404-B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib \u2013 a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"key":"2024050221001165500_kead404-B9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024050221001165500_kead404-B10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2024050221001165500_kead404-B11","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2024050221001165500_kead404-B12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/BOR.0000000000000837","article-title":"Polymyositis: does it really exist as a distinct clinical subset?","volume":"33","author":"Leclair","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2024050221001165500_kead404-B13","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63(Suppl 11)","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024050221001165500_kead404-B14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024050221001165500_kead404-B15","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2885","article-title":"Type 1 interferons and myositis","volume":"12(Suppl 1)","author":"Greenberg","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2024050221001165500_kead404-B16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/ard.2011.150284","article-title":"The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon","volume":"71","author":"Rosengren","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024050221001165500_kead404-B17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.22620","article-title":"Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness","volume":"67","author":"Paik","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024050221001165500_kead404-B18","doi-asserted-by":"crossref","first-page":"e12955","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko","year":"2021","journal-title":"Brain Pathol"},{"key":"2024050221001165500_kead404-B19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/medicina57121358","article-title":"Combination therapy with rituximab, tofacitinib and pirfenidone in a patient with rapid progressive interstitial lung disease (RP-ILD) due to MDA5 antibody-associated dermatomyositis: a case report","volume":"57","author":"Yen","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2024050221001165500_kead404-B20","doi-asserted-by":"crossref","first-page":"e002795","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"Ida","year":"2023","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead404\/51278607\/kead404.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/5\/1432\/57391295\/kead404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/5\/1432\/57391295\/kead404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T17:02:26Z","timestamp":1714669346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/5\/1432\/7243146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead404","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,8,16]]}}}